Glow LifeTech Corp (OTCMKTS:GLWLF) stock is up 41% in a month. Yesterday, the company announced the completion of the ordering of the reactor production machinery and commencement of the development of high-performance water-soluble MyCell marijuana ingredients at the Canadian processing plant.
On Tuesday, GLWLF stock ended flat at $0.2540 with 700 shares, compared to its average volume of 1K shares. The stock has moved within a range of $0.2540 – 0.2540 after opening trading at $0.2540.
Glow Completes Reactor Commissioning and Initiates Development of Proprietary MyCell(R) Water-Soluble Cannabis Ingredients
Artemic Support, presently undergoing a Long-Covid clinical trial and is slated to be finished by February 2022, is powered by MyCell technology. As a result, Glow will be able to manufacture a varied portfolio of high-bioavailability cannabis compounds that push the frontiers of performance and innovation after its licensed marijuana processing space is completed and the reactor is successfully commissioned.
The reactor is a crucial element of the Glow’s patented MyCell® Technology delivery system, which converts poorly absorbed cannabinoids like CBD and THC into water-soluble concentrates with rapid onset, high absorption, and precise dosing. COO Tom Gladwel said that this is a massive milestone for the company in the commercialization of the novel MyCell ingredients, which enables it to advance the creation of a breakthrough cannabis ingredients portfolio instantly. So, GLWLF is worth watching in the coming weeks.
“This is another major step forward in the commercialization of our innovative MyCell® ingredients and enables us to immediately advance the development of a portfolio of breakthrough cannabis ingredient solutions,” said Tom Glawdel, Chief Operating Officer, Glow LifeTech. “This represents the first operational production facility of MyCell® Technology outside of its native Switzerland and for the first time enables the supply of MyCell® cannabis ingredients to the North American market.”